Oral Presentation The 47th Lorne Conference on Protein Structure and Function 2022

Crystal and Cryo-EM structures provide insight into how pro-neurodegenerative SARM1 is activated and cleave NAD+ (#45)

Yun Shi 1 , Weixi Gu 2 , Jeff D Nanson 2 , Philip S Kerry 3 , Todd Bosanac 4 , Michael J Landsberg 2 , Bostjan Kobe 2 , Robert O Hughes 4 , Thomas Ve 1
  1. Institute for Glycomics, Griffith University, Southport, QLD 4222, Australia
  2. School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, QLD 4072, Australia
  3. Evotec (UK) Ltd, Abingdon, Oxfordshire OX14 4RZ, UK
  4. Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly & Co, Cambridge, USA

Axonal degeneration is responsible for disease progression and accumulation of disability in many neurodegenerative conditions. Sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1) is a nicotinamide adenine dinucleotide (NAD+)- cleaving enzyme whose activation triggers axon destruction [1-4]. Loss of the biosynthetic enzyme NMNAT2, which converts nicotinamide mononucleotide (NMN) to NAD+, activates SARM1 via an unknown mechanism. Using crystallography, cryo-EM, NMR and biochemical assays, we demonstrate that SARM1 is activated by an increase in the ratio of NMN to NAD+ and show that both metabolites compete for binding to the autoinhibitory N-terminal armadillo repeat (ARM) domain of SARM1 [5]. We show that NMN binding disrupts ARM-TIR interactions in the full-length SARM1 octamer, enabling its TIR domains to self-associate and form a catalytic site capable of cleaving NAD+. These structural insights identify SARM1 as a metabolic sensor of the NMN/NAD+ ratio, defines the mechanism of SARM1 activation and catalysis, and provide rational avenues for the design of new therapeutics targeting SARM1.

 

[1] Essuman, K. et al.(2017). Neuron 93, 1334-1343.

[2] Essuman, K. et al. (2018). Curr. Biol. 28, 421-430.

[3] Horsefield, S. et al. (2019). Science 365, 793-799.

[4] Wan, L. et al. (2019). Science 365, 799-803.

[5] Figley, M. Et al. (2021). Neuron 109, 1118–1136.